LinkedIn Profile

Access ImmusanT historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:immusant 1619924 May 29th, 2019 12:00AM ImmusanT, Inc. 636 20.00 Open Biotechnology May 28th, 2019 10:21PM May 28th, 2019 10:21PM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. Open Open One Kendall Square Cambridge MA US 02139 ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 17th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 16th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 15th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 14th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 13th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 12th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 11th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 10th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology
private:immusant 1619924 Feb 9th, 2018 12:00AM ImmusanT, Inc. 358 11.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter. ImmusanT Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.